Here's Why Regeneron Pharmaceuticals Just Hit A Record High

There are positive aspects to Regeneron Pharmaceuticals (REGN) beyond its popular drug Eylea, according to an analyst. While Eylea remains Regeneron’s top earner, the company’s allergic conditions treatment Dupixent and progress in its pipeline were the reasons behind the analyst’s upgrade of REGN stock. The analyst also raised the price target for the stock. In the first nine months of 2022, Dupixent sales surpassed $6.2 billion, and it has shown promise in treating other conditions. Regeneron is also working on other drugs, including fianlimab for lung cancer and linvoseltamab for multiple myeloma. The company is also exploring treatments for eye diseases, hearing restoration, cardiovascular diseases, and obesity.